Experimental pancreatic cancer vaccine triggers immune response in 90% of patients

An experimental pancreatic cancer vaccine has been tested in humans for the first time, producing a durable immune response in 90% of participants. Researchers say the results are promising and suggest the vaccine could potentially stop tumour development before it occurs. Further studies are needed to confirm its safety and efficacy.